Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
Pituitary neuroendocrine tumors (PitNET) are commonly benign tumors accounting for 10-25% of intracranial tumors. Prolactin-secreting adenomas represent the most predominant type of all PitNET and for this subtype of tumors, the medical therapy relies on the use of dopamine agonists (DAs). DAs yield...
Tallennettuna:
| Päätekijät: | , , , , , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Frontiers Media S.A.
2022-01-01
|
| Sarja: | Frontiers in Endocrinology |
| Aiheet: | |
| Linkit: | https://www.frontiersin.org/articles/10.3389/fendo.2021.791633/full |
| Tagit: |
Ei tageja, Lisää ensimmäinen tagi!
|